11 completed, 3 recruiting, 2 terminated, 1 unknown. 17 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 11, Recruiting 3, Terminated 2, Unknown 1 |
| Phase 2 | 4 | Completed 2, Recruiting 2 |
Follow Chromosome Aberrations: new trials by email Literature Review of Chromosome Aberrations trials Research Report on Chromosome Aberrations
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sovilnesib in Subjects With Ovarian Cancer Sovilnesib - High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer | Phase 1 | Recruiting | Volastra Therapeutics, Inc. | 150 | 2024-04-04 | 2026-10-13 |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer VLS-1488 - Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary | Phase 1 / Phase 2 | Recruiting | Volastra Therapeutics, Inc. | 200 | 2023-10-18 | 2025-11-04 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Low-Dose Ketamine in Children With ADNP Syndrome Ketamine - ADNP Syndrome | Phase 1 / Phase 2 | Completed | Alexander Kolevzon | 10 | 2020-08-19 | 2023-07-07 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML Selinexor, Daunorubicin, Cytarabine - Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 21 | 2015-06-18 | 2022-10-03 |
| Blastocyst Euploidy Assessment and Conditioned embryO traNsfer PGS - Infertility | Phase 1 | Unknown | Chinese PLA General Hospital | 1000 | 2014-11-01 | 2015-02-02 |
| Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2012-08-08 | 2020-03-05 |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Melphalan, Fludarabine, Mycophenolate mofetil - Blood And Marrow Transplantation, Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2012-07-13 | 2017-04-28 |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) Panobinostat - Acute Myeloid Leukemia (AML) | Phase 1 | Completed | Novartis Pharmaceuticals | 46 | 2010-10-01 | 2020-12-19 |
| Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential prematuration culture - Infertility | Phase 1 | Terminated | Universitair Ziekenhuis Brussel | 213 | 2009-05-01 | 2014-12-05 |
| Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential prematuration culture - Infertility | Phase 1 | Terminated | Universitair Ziekenhuis Brussel | 115 | 2009-01-01 | 2014-12-03 |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Radotinib - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Il-Yang Pharm. Co., Ltd. | 85 | 2008-07-01 | 2018-08-29 |
| Treatment Strategies for Children With Smith-Magenis Syndrome dTR Melatonin (NIH CC PDS), Phototherapy (Bright Light), Melatonin CR - Developmental Delay Disorders, Chromosome Deletion | Phase 1 | Completed | National Human Genome Research Institute (NHGRI) | 23 | 2007-07-17 | 2019-12-12 |
| Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Imatinib/Acetaminophen - Chronic Myeloid Leukemia (CML) | Phase 1 | Completed | Novartis Pharmaceuticals | 12 | 2006-11-01 | 2016-04-21 |
| Effect of Food on Bioavailability of Modified Release Formulations of Imatinib imatinib - Healthy | Phase 1 | Completed | Novartis | 32 | 2006-09-01 | 2016-04-05 |
| Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib imatinib - Healthy | Phase 1 | Completed | Novartis Pharmaceuticals | 16 | 2006-06-01 | 2016-04-05 |
Philadelphia Chromosome (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia (4) · Aneuploidy (3) · Infertility (3) · Leukemia, Myeloid, Acute (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Chromosomal Instability (2) · Leukemia, B-Cell (2) · Lymphoma, B-Cell (2) · Polycystic Ovary Syndrome (2)
Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Neoplasms (14) · Neoplasms by Histologic Type (11) · Hemic and Lymphatic Diseases (10) · Hematologic Diseases (9) · Translocation, Genetic (8) · Leukemia, Myeloid (7) · Bone Marrow Diseases (6) · Chronic Disease (6) · Disease Attributes (6) · Leukemia (6) · Myeloproliferative Disorders (6) · Genital Diseases (5)
Imatinib Mesylate (3) · fludarabine (3) · Acetaminophen (2) · Cyclophosphamide (2) · fludarabine phosphate (2) · 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide (1) · Antiemetics (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Blood Component Removal (1) · Blood Specimen Collection (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Clofarabine (1) · Cytarabine (1)
Novartis Pharmaceuticals (3) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Universitair Ziekenhuis Brussel (2) · Volastra Therapeutics, Inc. (2) · Alexander Kolevzon (1) · Chinese PLA General Hospital (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Il-Yang Pharm. Co., Ltd. (1) · National Human Genome Research Institute (NHGRI) (1) · Novartis (1)
United States (10) · Belgium (2) · South Korea (2) · China (1) · Germany (1) · India (1) · Spain (1) · Thailand (1)
Alexander Kolevzon, MD (1) · Elizabeth Shpall, MD (1) · IL-yang Pharm (1) · Jorge Cortes, MD (1) · Kendra Sweet, M.D. (1) · Nirali N Shah, M.D. (1) · Sara K Silbert, M.D. (1) · William A Gahl, M.D. (1)
PMID 24705186, PMID 25778529, PMID 31541945, PMID 32898291, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 38376944, PMID 42248607
2009 (1), P01CA148600 (1)